Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA May Change Requirements For CV Outcomes Trials For Type 2 Diabetes Drugs

Executive Summary

Endocrinologic and Metabolic Drugs Advisory Committee will reconsider 2008 guidance on evaluating CV risks in antidiabetic therapies at two-day meeting in October.


Related Content

US FDA Panel Will Reckon With Need For Diabetes Drug CV Risk Assessments
Recent And Upcoming FDA Advisory Committee Meetings
Novo Nordisk's Victoza Adds CV Benefit Claim, But Not For Primary Prevention
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple
Jardiance Mortality Claim Narrowly Endorsed By FDA Advisory Committee
Will CV Verdicts For Onglyza, Nesina Cause FDA To Change Its Tune On Antidiabetic Safety?
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs
FDA Should Require Cardiovascular Outcomes Trials For All Type 2 Diabetes Drugs, Panel Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts